The June 10, 2017, article by Zucca et al, entitled “Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy” (J Clin Oncol https://doi.org/10.1200/JCO.2016.70.6994), was published with errors.
Dr. Copie-Bergman was incorrectly listed as an author. Dr. Anne Moreau should have been listed instead as the 25th author. Dr. Copie-Bergman should have been removed from the author list, affiliation, and contribution sections.
Dr. Moreau’s affiliation was University Hospital of Nantes, Nantes, France. Her contributions to the manuscript included data analysis and interpretation, manuscript writing and final approval of the manuscript. She had no conflicts of interest to disclose.
Under the Pathology Expert Panel, Anne Moreau’s last name was given incorrectly as “Moreaud,” however, her name should have been listed as Anne Moreau.
In figure 1, the n for “Randomly assigned” was incorrectly given as 452, but it should have been (N = 454). Under ARM B, the n for “Rituximab + Chlorambucil” was incorrectly given as 151, however it should have been (n = 152). ARM A was also listed twice. The ARM A provided in the gray box should have been ARM C. Arrows were missing pointing down from ARM C to (n = 144) to Analyzed (n = 138).
In figure A1 (online only) the legend should be changed from “lymphoid tissue (MALT lymphoma) in …” to “lymphoid tissue (MALT) lymphoma …”
The online version has been corrected in departure from the print. The authors apologize for the errors.